Search - tctmd.com

Displaying 1 - 20 of 43

Sort: Relevancy | Date

Presentation TCT 2016

Case Conclusion: How Did I Treat?

Presenter: Runlin Gao, Bo Xu, Junjie Zhang

November 01, 2016

Presentation TCT 2016

How Would I Treat? (Option 2)

Presenter: Runlin Gao, Bo Xu, Qi Zhang

November 01, 2016

Presentation TCT 2016

How Would I Treat? (Option 1)

Presenter: Runlin Gao, Bo Xu, Jian Liu

November 01, 2016

Presentation TCT 2016

Case Introduction: How Should I Treat?

Presenter: Runlin Gao, Bo Xu, Junjie Zhang

November 01, 2016

Presentation TCT 2016

Case Conclusion: How Did I Treat?

Presenter: Runlin Gao, Bo Xu, Kefei Dou

November 01, 2016

Presentation TCT 2016

How Would I Treat? (Option 2)

Presenter: Runlin Gao, Bo Xu, Zening Jin

November 01, 2016

Presentation TCT 2016

How Would I Treat? (Option 1)

Presenter: Runlin Gao, Bo Xu, Philippe Généreux

November 01, 2016

Presentation TCT 2016

Case Introduction: How Should I Treat?

Presenter: Runlin Gao, Bo Xu, Kefei Dou

November 01, 2016

Presentation TCT 2016

PARTNER I FIVE-YEAR ECHO: Long-term Hemodynamic and Structural Outcomes After Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Aortic Stenosis

Presenter: Gregg W. Stone, Philippe Pibarot, Pamela S. Douglas

November 01, 2016

Presentation TCT 2016

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Presenter: Gregg W. Stone, Philippe Pibarot, David J. Cohen

November 01, 2016

Presentation TCT 2016

Case #3: A Novel Issue With a Bioresorbable Scaffold

Presenter: Antonio Colombo, Jeffrey W. Moses, Carlo Di Mario

October 31, 2016

Presentation TCT 2016

Case 3:

Presenter: Parag Barwad, Raju Narasa Kavalipati, Narenda N. Khanna, Fazila T. Malik, Manotosh Panja, Gokul M. Reddy, Kamal K. Sethi, Rabin dra Nath Chakraborty

October 31, 2016

Presentation TCT 2016

Case 3: Heavily Calcified Vessel

Presenter: Jun-Jack Cheng, Gary S. Mintz, Chiung Jen Wu, Wen-Lieng Lee

October 31, 2016

Presentation TCT 2016

PARTNER 2 and SAPIEN 3 Critique: Pros and Cons

Presenter: William A. Gray, Stephan Windecker

October 31, 2016

Presentation TCT 2016

Trial #6 - The Essentials ofPARTNER 2 and SAPIEN 3 - TAVR In Intermediate Risk Patients, and Improved TAVR Devices

Presenter: William A. Gray, Stephan Windecker, Vinod H. Thourani

October 31, 2016

Presentation TCT 2016

TCT 36: Frailty in Intermediate Risk Patients Undergoing Transcatheter or Surgical Aortic Valve Replacement, Cut Points and Relationship With Outcomes: An Analysis of the Placement of Aortic Transcatheter Valves (PARTNER) 2 Cohort A Randomized Trial

Presenter: Charles J. Davidson, Michael J. Reardon, Philip Green

October 31, 2016

Title Effect of Sapien-3 Transcatheter Valve Implant on Health Status in Patients with Severe Aortic Stenosis at Intermediate Surgical Risk: Results from the PARTNER S3i Trial

Presentation TCT 2016

TCT 34: Effect of Sapien-3 Transcatheter Valve Implant on Health Status in Patients with Severe Aortic Stenosis at Intermediate Surgical Risk: Results from the PARTNER S3i Trial

Presenter: Charles J. Davidson, Michael J. Reardon, Suzanne Baron

October 31, 2016

Presentation TCT 2016

Case #3: CTO PCI: Keep It Simple

Presenter: Afzalur Rahman, Kaisar Nasrullah Khan

October 30, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Michael J. Mack

October 30, 2016

Presentation TCT 2016

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Susheel K. Kodali

October 30, 2016

Advertisement

Case Conclusion: How Did I Treat?

How Would I Treat? (Option 2)

How Would I Treat? (Option 1)

Case Introduction: How Should I Treat?

Case Conclusion: How Did I Treat?

How Would I Treat? (Option 2)

How Would I Treat? (Option 1)

Case Introduction: How Should I Treat?

PARTNER I FIVE-YEAR ECHO: Long-term Hemodynamic and Structural Outcomes After Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Aortic Stenosis

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Case #3: A Novel Issue With a Bioresorbable Scaffold

Case 3:

Case 3: Heavily Calcified Vessel

PARTNER 2 and SAPIEN 3 Critique: Pros and Cons

Trial #6 - The Essentials ofPARTNER 2 and SAPIEN 3 - TAVR In Intermediate Risk Patients, and Improved TAVR Devices

TCT 36: Frailty in Intermediate Risk Patients Undergoing Transcatheter or Surgical Aortic Valve Replacement, Cut Points and Relationship With Outcomes: An Analysis of the Placement of Aortic Transcatheter Valves (PARTNER) 2 Cohort A Randomized Trial

TCT 34: Effect of Sapien-3 Transcatheter Valve Implant on Health Status in Patients with Severe Aortic Stenosis at Intermediate Surgical Risk: Results from the PARTNER S3i Trial

Case #3: CTO PCI: Keep It Simple

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content